Exelixis EXEL
NASDAQ EXEL
$59.02 -0.11 (-0.19%)
As of: Sep 4, 2026 · 3:59 PM EDT

Exelixis (EXEL) Non-Current Deffered Revenue (2010 - 2023)

Exelixis (EXEL) posted quarterly Non-Current Deffered Revenue of $6.7 million for Q2 2023, down 6.73% year-over-year from $7.2 million in Q2 2022, and up 6.75% quarter-over-quarter from $6.3 million in Q1 2023.

Analysis

Exelixis (EXEL) Non-Current Deffered Revenue (2010 - 2023) Analysis & Trends

Exelixis' Non-Current Deffered Revenue history runs 11 years deep, the most recent figure standing at $6.7 million for Q2 2023.

  • In Q2 2023, Non-Current Deffered Revenue fell 6.73% year-over-year to $6.7 million; the TTM figure through Jun 2023 stood at $6.7 million (down 6.73% YoY), while the FY2022 annual figure was $6.6 million, down 24.68% from the prior year.
  • Non-Current Deffered Revenue for Q2 2023 stood at $6.7 million, up from $6.3 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $16.6 million in Q2 2019, with the low at $3.8 million in Q1 2021.
  • The 5-year median for Non-Current Deffered Revenue is $8.4 million (2019), against an average of $9.3 million.
  • The sharpest annual moves came in 2019 and 2020: Non-Current Deffered Revenue soared 579.01% in 2019, then plunged 58.51% in 2020.
  • Exelixis' Non-Current Deffered Revenue stood at $15.4 million in 2019, then sank by 39.47% to $9.3 million in 2020, then decreased by 6.25% to $8.7 million in 2021, then declined by 24.68% to $6.6 million in 2022, then increased by 2.16% to $6.7 million in 2023.
  • Business Quant data shows EXEL's Non-Current Deffered Revenue at $6.7 million in Q2 2023, $6.3 million in Q1 2023, and $6.6 million in Q4 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 220.40 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 147.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 Exelixis 14.81 Bn 13.97 Bn 608.03 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 6.72 Mn
Mar 31, 2023 6.30 Mn
Dec 30, 2022 6.58 Mn
Sep 30, 2022 6.49 Mn
Jul 1, 2022 7.21 Mn
Apr 1, 2022 8.04 Mn
Dec 31, 2021 8.74 Mn
Oct 1, 2021 9.44 Mn
Jul 2, 2021 8.58 Mn
Apr 2, 2021 9.76 Mn
Jan 1, 2021 3.76 Mn
Oct 2, 2020 9.32 Mn
Jul 3, 2020 15.00 Mn
Apr 3, 2020 14.13 Mn
Jan 3, 2020 6.60 Mn
Sep 27, 2019 15.40 Mn
Jun 28, 2019 16.63 Mn
Mar 29, 2019 8.32 Mn
Dec 28, 2018 15.90 Mn
Sep 28, 2018 2.27 Mn